NDA Clinical Briefing Package Submitted to the US FDA
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Zircon P3 IND submitted to US FDA
- Telix and Vic Cancer Centre receive Cancer Australia grant
- Telix and ATONCO Partner for Bladder Cancer
- Telix and AusHealth Partner for Lung, Ovarian Cancer
- Appendix 4C - September 2019 quarter
Later from Telix Pharmaceuticals
- Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
- Appendix 4C - December 2019 Quarter
- Appendix 4E - Summary of Results
- Positive FDA feedback on NDA submission process
- Telix and partners receive 500k CRC research grant
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals